• Tara C Jatlaoui, Jennifer L Wiltz, Sarah Kabbani, David A Siegel, Ram Koppaka, Michele Montandon, Susan Hocevar Adkins, David N Weissman, Emily H Koumans, Michelle O'Hegarty, Megan C O'Sullivan, Matthew D Ritchey, Kevin Chatham-Stephens, Emily A Kiernan, Mark Layer, Sarah Reagan-Steiner, Jaswinder K Legha, Katherine Shealy, Brian A King, Christopher M Jones, Grant T Baldwin, Dale A Rose, Lisa J Delaney, Peter Briss, Mary E Evans, and Lung Injury Response Clinical Working Group.
• MMWR Morb. Mortal. Wkly. Rep. 2019 Nov 22; 68 (46): 1081-1086.

AbstractCDC, the Food and Drug Administration (FDA), state and local health departments, and public health and clinical stakeholders are investigating a nationwide outbreak of e-cigarette, or vaping, product use-associated lung injury (EVALI) (1). CDC has published recommendations for health care providers regarding EVALI (2-4). Recently, researchers from Utah and New York published proposed diagnosis and treatment algorithms for EVALI (5,6). EVALI remains a diagnosis of exclusion because, at present, no specific test or marker exists for its diagnosis, and evaluation should be guided by clinical judgment. Because patients with EVALI can experience symptoms similar to those associated with influenza or other respiratory infections (e.g., fever, cough, headache, myalgias, or fatigue), it might be difficult to differentiate EVALI from influenza or community-acquired pneumonia on initial assessment; EVALI might also co-occur with respiratory infections. This report summarizes recommendations for health care providers managing patients with suspected or known EVALI when respiratory infections such as influenza are more prevalent in the community than they have been in recent months (7). Recommendations include 1) asking patients with respiratory, gastrointestinal, or constitutional symptoms about the use of e-cigarette, or vaping, products; 2) evaluating those suspected to have EVALI with pulse oximetry and obtaining chest imaging, as clinically indicated; 3) considering outpatient management for clinically stable EVALI patients who meet certain criteria; 4) testing patients for influenza, particularly during influenza season, and administering antimicrobials, including antivirals, in accordance with established guidelines; 5) using caution when considering prescribing corticosteroids for outpatients, because this treatment modality has not been well studied among outpatients, and corticosteroids could worsen respiratory infections; 6) recommending evidence-based treatment strategies, including behavioral counseling, to help patients discontinue using e-cigarette, or vaping, products; and 7) emphasizing the importance of annual influenza vaccination for all persons aged ≥6 months, including patients who use e-cigarette, or vaping products.

12 keywords...

hide…